Skip to main content

Advertisement

SpringerLink
Log in

FGF23 and the parathyroid glands

  • Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Fibroblast growth factor 23 (FGF23) is a phosphatonin that is secreted by osteocytes and osteoblasts in response to hyperphosphatemia and 1,25-dihydroxyvitamin D (1,25D). It acts on its receptor complex, Klotho–FGFR1c (fibroblast growth factor receptor 1 c-splicing form), in the distal convoluted tubule to repress renal phosphorus reabsorption in the proximal tubule and suppress the renal synthesis of 1,25D. Klotho–FGFR1c is also expressed in the parathyroid glands. FGF23 acts on the receptor complex in the parathyroid glands to decrease parathyroid hormone (PTH) gene expression and PTH secretion through activation of the MAPK pathway. In chronic kidney disease (CKD), both FGF23 and PTH are increased, implying resistance of the parathyroid glands to FGF23. There is a decrease in the Klotho–FGFR1c complex in the parathyroid glands in both experimental CKD and in patients with end-stage renal disease. In addition, in advanced experimental CKD, FGF23 has a decreased ability to inhibit PTH expression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310–1315

    Article  CAS  PubMed  Google Scholar 

  2. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K (2009) Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 45:1161–1168

    Article  CAS  PubMed  Google Scholar 

  3. Feng JQ, Ye L, Schiavi S (2009) Do osteocytes contribute to phosphate homeostasis? Curr Opin Nephrol Hypertens 18:285–291

    Article  CAS  PubMed  Google Scholar 

  4. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2002) Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179–3182

    Article  CAS  PubMed  Google Scholar 

  5. White KE, Evans WE, O’Riordan JLH, Speer MC, Econs MJ, Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348

    Article  CAS  Google Scholar 

  6. Quarles LD (2008) Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118:3820–3828

    Article  CAS  PubMed  Google Scholar 

  7. Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, Juppner H (2010) Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 95:578–585

    Article  CAS  PubMed  Google Scholar 

  8. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592

    Article  CAS  PubMed  Google Scholar 

  9. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24:2792–2796

    Article  CAS  PubMed  Google Scholar 

  10. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120–6123

    Article  CAS  PubMed  Google Scholar 

  11. Razzaque MS, Sitara D, Taguchi T, St Arnaud R, Lanske B (2006) Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 20:720–722

    CAS  PubMed  Google Scholar 

  12. Farrow EG, Davis SI, Summers LJ, White KE (2009) Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20:955–960

    Article  CAS  PubMed  Google Scholar 

  13. Takeshita K, Fujimori T, Kurotaki Y, Honjo H, Tsujikawa H, Yasui K, Lee JK, Kamiya K, Kitaichi K, Yamamoto K, Ito M, Kondo T, Iino S, Inden Y, Hirai M, Murohara T, Kodama I, Nabeshima Y (2004) Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation 109:1776–1782

    Article  PubMed  Google Scholar 

  14. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, Fujimori T, Nabeshima Y (2004) Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 565:143–147

    Article  CAS  PubMed  Google Scholar 

  15. Fukumoto S, Yamashita T (2002) Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens 11:385–389

    Article  PubMed  Google Scholar 

  16. Alexander RT, Woudenberg-Vrenken TE, Buurman J, Dijkman H, van der Eerden BC, van Leeuwen JP, Bindels RJ, Hoenderop JG (2009) Klotho prevents renal calcium loss. J Am Soc Nephrol 20:2371–2379

    Article  CAS  PubMed  Google Scholar 

  17. Isakova T, Gutierrez O, Shah A, Castaldo L, Holmes J, Lee H, Wolf M (2008) Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 19:615–623

    Article  CAS  PubMed  Google Scholar 

  18. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205–2215

    Article  CAS  PubMed  Google Scholar 

  19. Ix JH, Shlipak MG, Wassel CL, Whooley MA (2010) Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 25:993–997

    Article  CAS  PubMed  Google Scholar 

  20. Mirza MA, Hansen T, Johansson L, Ahlstrom H, Larsson A, Lind L, Larsson TE (2009) Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 24:3125–3131

    Article  CAS  PubMed  Google Scholar 

  21. Ben Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003–4008

    CAS  PubMed  Google Scholar 

  22. Yamashita T, Konishi M, Miyake A, Inui K, Itoh N (2002) Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 277:28265–28270

    Article  CAS  PubMed  Google Scholar 

  23. Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125–131

    Article  CAS  PubMed  Google Scholar 

  24. Lavi-Moshayoff V, Silver J, Naveh-Many T (2009) Human PTH gene regulation in vivo using transgenic mice. Am J Physiol Renal Physiol 297:F713–F719

    Article  CAS  PubMed  Google Scholar 

  25. Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T (2008) Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23:1509–1518

    Article  CAS  PubMed  Google Scholar 

  26. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T (2010) Resistance of the parathyroid to FGF23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 77:211–218

    Article  CAS  PubMed  Google Scholar 

  27. Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, Tominaga Y, Otsuki N, Nibu KI, Nakagawa K, Tsugawa N, Okano T, Kitazawa R, Fukagawa M (2010) Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77:232–238

    Article  CAS  PubMed  Google Scholar 

  28. Komaba H, Fukagawa M (2009) FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 77:292–298

    Article  PubMed  Google Scholar 

  29. Kumata C, Mizobuchi M, Ogata H, Koiwa F, Nakazawa A, Kondo F, Kadokura Y, Kinugasa E, Akizawa T (2010) Involvement of Alpha-Klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am J Nephrol 31:230–238

    Article  CAS  PubMed  Google Scholar 

  30. Lafage-Proust MH (2010) Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients? Kidney Int 77:390–392

    Article  CAS  PubMed  Google Scholar 

  31. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305–1315

    Article  CAS  PubMed  Google Scholar 

  32. Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M (2005) Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 101:c94–c99

    Article  CAS  PubMed  Google Scholar 

  33. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD (2010) Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 5:110–116

    Article  CAS  PubMed  Google Scholar 

  34. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y (2007) Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18:2683–2688

    Article  CAS  PubMed  Google Scholar 

  35. Brown WW, Juppner H, Langman CB, Price H, Farrow EG, White KE, McCormick KL (2009) Hypophosphatemia with elevations in serum FGF23 in a child with Jansen’s metaphyseal chondrodysplasia. J Clin Endocrinol Metab 94:17–20

    Article  CAS  PubMed  Google Scholar 

  36. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T (2005) Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289:F1088–F1095

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by grants from the Israel Science Foundation and the Israel Ministry of Health.

Author information

Authors and Affiliations

  1. Minerva Center for Calcium and Bone Metabolism, Nephrology Services, Hadassah Hebrew University Medical Center, Ein Karem, Jerusalem, 91120, Israel

    Justin Silver & Tally Naveh-Many

Authors
  1. Justin Silver
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tally Naveh-Many
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Justin Silver or Tally Naveh-Many.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silver, J., Naveh-Many, T. FGF23 and the parathyroid glands. Pediatr Nephrol 25, 2241–2245 (2010). https://doi.org/10.1007/s00467-010-1565-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-010-1565-3

Keywords

Search

Navigation